Want to see VYGR full AI Analyst Report?

Voyager Therapeutics (VYGR) Earnings Dates, Call Summary & Reports

1,380 Followers

Earnings Data

Report Date

Jul 30, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.5

Last Year’s EPS

-0.57

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 6 Analysts Ratings

Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 11, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.

Company Guidance

During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.

Strong Cash Position and Potential Milestone Payments

Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.

Advancements in Tau Silencing Program

The tau silencing gene therapy program, VY1706, moved forward into IND-enabling studies, showing 50% to 73% knockdown of tau messenger RNA in non-human primate studies.

Positive Results for Anti-Tau Antibody VY7523

VY7523 performed well in a single ascending dose study with no serious adverse events, showing dose-proportional pharmacokinetics and a CSF to serum ratio of 0.3%.

Promising External Data Supporting Anti-Tau Strategies

UCB's bepranemab demonstrated impact on tau accumulation, and further data from Merck and other companies are anticipated, which may support the potential of tau-targeted therapies.

Progress in Partnered Programs with Neurocrine

Two programs with Neurocrine are expected to enter the clinic or have an IND filed this year, indicating positive collaboration progress.

Voyager Therapeutics (VYGR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VYGR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2026	2026 (Q2)	-0.50 / -	-0.57	―	―	―
May 07, 2026	2026 (Q1)	-0.55 / -0.47	-0.53	11.32% (+0.06)	―	―
Mar 09, 2026	2025 (Q4)	-0.51 / -0.46	-0.59	22.03% (+0.13)	―	―
Nov 10, 2025	2025 (Q3)	-0.52 / -0.47	-0.16	-193.75% (-0.31)	―	―
Aug 06, 2025	2025 (Q2)	-0.53 / -0.57	-0.18	-216.67% (-0.39)	―	―
May 06, 2025	2025 (Q1)	-0.45 / -0.53	-0.2	-165.00% (-0.33)	―	―
Mar 11, 2025	2024 (Q4)	-0.37 / -0.59	1.25	-147.20% (-1.84)	―
Nov 12, 2024	2024 (Q3)	-0.45 / -0.16	-0.59	72.88% (+0.43)	―
Aug 06, 2024	2024 (Q2)	-0.41 / -0.18	-0.51	64.71% (+0.33)	―
May 13, 2024	2024 (Q1)	-0.44 / -0.20	2.94	-106.80% (-3.14)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VYGR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	$3.96	$4.05	+2.27%
Mar 09, 2026	$4.11	$5.00	+21.65%
Nov 10, 2025	$4.23	$4.26	+0.71%
Aug 06, 2025	$3.40	$3.22	-5.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Voyager Therapeutics Inc. (VYGR) report earnings?

Voyager Therapeutics Inc. (VYGR) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).

What is Voyager Therapeutics Inc. (VYGR) earnings time?

Voyager Therapeutics Inc. (VYGR) earnings time is at Jul 30, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VYGR EPS forecast?

VYGR EPS forecast for the fiscal quarter 2026 (Q2) is -0.5.